Combined therapy with deferiprone and desferrioxamine in thalassemia major

Haematologica

Volumn 90, Issue 10, 2005, Pages 1304-1305

  Loukopoulos, Dimitrios ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

AGRANULOCYTOSIS; ARTHROPATHY; CLINICAL TRIAL; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; NEUTROPENIA; PATIENT; SIDE EFFECT; THALASSEMIA MAJOR; UNITED KINGDOM;

BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES;

EID: 27144514670     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini D, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004,89:1187-93.
2. Hider RC, Singh S, Porter JB, Huehns ER. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann NY Acad Sci 1990;612:327-38.
3. Kontoghiorgis JG, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in beta thalassemia with the oral chelator 1,2-dimethyl-hydroxypyrid-4-one. Br Med J 1987;295:1509-12.
4. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4.
5. th Intl. Conference on Thalassaemia and the Haemoglobinopathies. Bangkok, Thailand, 1999:[Abstract 0018].
6. Orriga R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desfoerrioxamine in thalassemia major. Haematologica 2005;90:1163-8.
7. Ceci A, Balardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-6.
8. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subsutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. The Lancet 2002; 360:516-20.
9. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
10. Cohen A, Galanello R, Piga A Safety and effectiveness of long term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7.